May 2026

Corporate Overview

Redefining Possibilities in Rare Disease

Jazz Pharmaceuticals

Transforming Lives. Redefining Possibilities.

Caution Concerning Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, statements related to: the company's growth prospects and future financial and operating results, including the company's 2026 financial guidance and the company's expectations related thereto, including with respect to anticipated near-term catalysts and expectations for total revenue growth and double-digit growth for combined rare oncology and epilepsy franchises; the company's advancement of pipeline programs and the timing of development activities, regulatory activities, approvals, and submissions related thereto; the potential for a near-term commercial launch of zanidatamab in 1L HER2+ GEA in the U.S., if approved; planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof, including: the second interim OS data from the Phase 3 HERIZON trial of zanidatamab in 1L GEA, the top-line data from the EmpoweHER-BC-303 trial in breast cancer and top-line data from the Phase 3 ACTION trial of Modeyso in recurrent H3 K27M-mutant diffuse glioma; the company's development, regulatory and commercialization strategy; the company's expectations with respect to its products and product candidates and the potential of the company's products and product candidates and the potential regulatory path related thereto, including zanidatamab's potential to become the HER2-targeted therapy of choice in 1L HER2+ GEA, regardless of PD-L1 status and other HER2-expressing cancers; the company's capital allocation and corporate development strategy; the potential successful future development, manufacturing, regulatory and commercialization activities; the company's ability to realize the commercial potential of its products; the company's net product sales and goals for net product sales from new and acquired products; the company's views and expectations relating to its patent portfolio, including with respect to expected patent protection, as well as expectations with respect to exclusivity; the company's clinical trials confirming clinical benefit or enabling regulatory submissions, including the potential of the ongoing Phase 3 ACTION trial to confirm clinical benefit of Modeyso in recurrent H3 K27M-mutant diffuse glioma and extend to use in 1L patients; and other statements that are not historical facts. These forward-looking statements are based on the company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of, and revenue from, Xywav, Epidiolex/ Epidyolex, Ziihera, Modeyso, Zepzelca and other lead marketed products; effectively launching and commercializing the company's other products and product candidates; the successful completion of development and regulatory activities with respect to the company's product candidates; obtaining and maintaining adequate coverage and reimbursement for the company's products; the time-consuming and uncertain regulatory approval process, including the risk that the company's current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all, including the risk that zanidatamab in 1L HER2+ GEA may not be approved in a timely manner or at all; the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the company's business operations and financial results; protecting and enhancing the company's intellectual property rights and the company's commercial success being dependent upon the company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; delays or problems in the supply or manufacture of the company's products and product candidates, including due to geopolitical tensions and military conflicts; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired products, product candidates and businesses; the company's ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the company's cash flows and capital resources; the company's ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; fluctuations in the market price and trading volume of the company's ordinary shares; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in the company's Securities and Exchange Commission filings and reports, including the company's Annual Report on Form 10-K for the year ended December 31, 2025 and future filings and reports by the company. Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.

Transforming Lives. Redefining Possibilities.

Non-GAAP Financial Measures

To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. GAAP, the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presentation. The company presents non-GAAP ANI (and the related per share measure) and certain line item components as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP ANI (and the related per share measure) and its line item components exclude from GAAP reported net income (loss) (and the related per share measure) and its line item components certain items, as detailed in the reconciliation tables that follow in the Appendix hereto, and in the case of non-GAAP ANI (and the related per share measure), adjust for the income tax effect of the non-GAAP adjustments. In this regard, the components of non-GAAP ANI, including non-GAAP adjusted cost of product sales, SG&A expenses and R&D expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP ANI measure.

The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts and that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance. The company's management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for the company's management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles in the reconciliation tables that follow. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by the company in this presentation and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

At Jazz, we are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options






Strong 1Q26 Execution Across Franchises Sets Up For Full-Year Success

1Q26 Execution Highlights

Commercial:

- **Xywav** (+18% YoY)
- **Epidiolex** (+15% YoY)
- **Zepzelca** (+60% YoY)

R&D:

- **Practice-changing** 1L HER2+ GEA data[1] at ASCO GI derisks **$2B+ opportunity**
- Completed sBLA with FDA granting **Priority Review**; PDUFA date of **August 25, 2026**

Financial Strength

Outstanding 1Q26:

- **$1.1 billion in revenues (+19% YoY)**
- **Highest ever** 1Q revenues
- **Double-digit growth** across **all** promoted brands, strong contribution from ongoing Modeyso and Zepzelca (1LM) launches

Robust balance sheet:

- Cash[2] at end of 1Q26: **$2.9B**
- YTD operating cash flow: **$408M**

Upcoming Milestones

- Zanidatamab data **accepted for publication** by major journal
- HERIZON-GEA-01 **interim OS data** mid-2026
- Zanidatamab GEA **approval and launch** on or before PDUFA date (August 25, 2026)
- Modeyso **ACTION trial data** late 2026/early 2027
- EmpowHER-BC-303 trial enrolling, **data expected** late 2027 / early 2028
- Zanidatamab pipeline **continues to progress**
- Opportunity for additional **Business Development** in rare disease

[1]Data as presented by Elimova et.al ASCO GI 2026; [2]Cash includes cash, equivalents, and marketable securities as of March 31, 2026.

Refined Strategic Focus on Rare Disease

Attractive Growth Market That Plays to Jazz's Strengths

RARE ONCOLOGY

RARE EPILEPSY

RARE SLEEP

NEW RARE THERAPEUTIC AREAS

Rare Disease

- High unmet need
- Small patient populations
- Concentrated call points
- Differentiated support services
- Lower competitive intensity
- Attractive peak revenue opportunity for Jazz
- Favorable regulatory and policy dynamics

Strong Corporate Development Track Record in Rare Disease

ZEPZELCA	GW ACQUISITION	ZANIDATAMAB	Chimerix Acquisition
Rapidly Accretive Transaction	*Transformational Transaction*	*Significant Oncology Development Transaction*	*Added Neuro-Oncology Expertise*
• **>$1.6B**[1] in revenue since launch in mid-2020 • In 2025, received FDA **approval and launched in 1LM ES-SCLC** based on practice-changing IMforte[2] trial results	• **Durable** and **long-lived asset** in Epidiolex • **~$4.3B**[3] in revenue since acquisition mid-2021 • **Achieved blockbuster status** with **>$1B** revenues in 2025 • Expanded operational footprint and **in-house R&D capabilities**	• Potential **launch in GEA** on or before **PDUFA date of August 25** • Significant **regulatory progress** with **extensive development program ongoing** • **De-risked** near-term opportunity with **$2B+ peak sales potential**	• **Successful launch** of Modeyso with **strong early performance**, $41M in revenue for 1Q26 • Compelling opportunity with **$500M+** U.S. peak sales potential • **Continued value enhancement** through deferred tax asset and PRV sale

2020 → **2021** → **2022** → **2025**

[1]Net product sales from launch in July 2020 to March 31, 2026; [2]IMforte study done in collaboration with F. Hoffmann-La Roche Ltd; [3]Net product sales from acquisition in May 2021 to March 31, 2026.

Key Commercial Products

Highly Differentiated Medicines for Patients with Serious Diseases

Jazz Pharmaceuticals

Successful Commercial Execution in Rare Disease

20+ years of experience building a diverse portfolio of products that make a difference for patients and their families

Rare Sleep

xywav™

Leader in Sleep

Proven commercial capabilities

Xywav remains #1 branded treatment for narcolepsy[1]

Rare Epilepsy

Epidiolex®

Epidyolex® cannabidiol Oral solution

Blockbuster revenue in 2025

Exclusivity into the very late 2030's

Epidiolex is the #1 branded epilepsy treatment[2]

Rare Oncology

ZIIHERA® (zanidatamab-hrii) 50mg/ml Injection for IV

MODEYSO™ (dordaviprone) capsules 125 mg

RYLAZE® asparaginase erwinia chrysanthemi (recombinant)-rywn for injection 10mg/0.5mL per vial

ENRYLAZE

ZEPZELCA® (lurbinectedin) for injection 4 mg

DEFITELIO® (defibrotide sodium) injection 80 mg/mL

Vyxeos® (daunorubicin and cytarabine) 44 mg/100 mg per vial liposome for injection

[1]Based on 1Q26 Xywav net product sales; [2]Based on 1Q26 Epidiolex net product sales.

Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity

Cindy
Xywav patient living with IH

xywav™

Xywav remains the #1 branded treatment for narcolepsy[1]

- Benefits of **highly efficacious and safer** treatment option due to **reduced sodium content** and an **individualized dosing regimen** continue to resonate with patients and HCPs
- **FDA** published its summary of **clinical superiority findings** stating Xywav is clinically superior to Xyrem by **means of greater safety**
- JazzCares services and field nurse educator program **helping patients navigate initiation of Xywav treatment**
- See **most opportunity for patient growth in IH** as the only approved therapy to treat IH and no near-term competition

[1]Based on 1Q26 Xywav net product sales.

Epidiolex: Durable Growth with High Unmet Need

Corey
Epidiolex patient living with LGS

Epidiolex® Epidyolex® cannabidiol Oral solution

Epidiolex is the #1 branded epilepsy treatment[1]

- Continued education on **synergies from treatment in combination with clobazam**
- **Further data generation**, including **beyond-seizure benefits** from the EpiCom[2] study in TSC and nurse-reported responses to the BECOME[3] survey in long-term care facilities
- **JazzCares** suite of services along with the **Nurse Navigator program** helps patients, families, and HCPs navigate treatment-related topics
- Further development opportunities, including new formulation work, with a focus on growth in **adult patient setting**

[1]Based on 1Q26 Epidiolex net product sales; [2]Eeghen, A., et al. Poster presented at: American Epilepsy Society 2025 Annual Meeting, December 5-9, 2025. Atlanta; [3]Wrobel, N. Poster presented at: American Academy of Neurology 2025 Annual Meeting, April 5-9. San Diego, CA.

Zepzelca: Opportunity to Redefine 1L ES-SCLC Treatment Paradigm

Donna
Former Zepzelca patient diagnosed with SCLC

ZEPZELCA® (lurbinectedin) for injection 4 mg

FDA approved Zepzelca in combination with Tecentriq as first-line maintenance therapy for ES-SCLC in 4Q25

- Included in **NCCN Guidelines** as a **preferred regimen**
- **Addresses significant unmet need:** IMforte trial results[1] shows mOS of **13.2 months** vs 10.6 months for atezolizumab alone from the point of randomization
- Potential to **increase duration of response** with earlier line patients
- In the U.S., there are **~30,000 1L SCLC patients**, with **~27,000** currently treated in the front-line[2], with 70% of 1L SCLC patients diagnosed with extensive-stage disease[3]

[1]IMforte data presented at ASCO 2025, IMforte study done in collaboration with F. Hoffmann-La Roche Ltd; [2]Approximate U.S. SCLC patient numbers, sources: SEER Cancer Stat Factshttps://seer.cancer.gov/statfacts/html/lungb.html, accessed April 19, 2019, American Cancer Society, https://www.cancer.org/cancer/small-cell-lung-cancer/about/what-is-small-cell-lung-cancer.html, accessedApril 12, 2019, Kantar Health Treatment Architecture SCLC July 2018, Jazz primary market research May 2019; [3]SHS claims data ending September 2024;Tx Onc data ending October2024; Onmark UnityData ending October 2024; IntrinsiQ ION data ending October 2024.

Rely on Rylaze: Critical Component of U.S. ALL/LBL Treatment Protocols

Willow
Rylaze patient diagnosed with ALL

RYLAZE® asparaginase erwinia chrysanthemi (recombinant)-rywn for injection 10mg/0.5mL per vial

ENRYLAZE

Sustained asparaginase activity over the course of therapy essential to treatment success of ALL/LBL patients[1]

- **Only therapy available** to patients in the U.S. who have a **hypersensitivity reaction** to *E. coli*-derived asparaginase

Continued focus on:

- Increased use in **adolescent/young adult** setting
- Efforts to ensure patients **switch to Rylaze at first sign of hypersensitivity reaction** or due to treatment-related issues

[1]Salzer W, Bostrom B, Messinger Y, et al. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(8):1797-1806.

Ziihera: De-Risked Near-Term Opportunity with $2B+ Peak Potential

ZIIHERA® (zanidatamab-hrii) 50mg/ml Injection for IV

Goal to be the HER2-targeted agent of choice

- sBLA granted Priority Review; PDUFA date of August 25, 2026
- NCCN submission complete; accepted for publication in major journal
- Customer-facing team in place and prepared for GEA launch

Biliary Tract Cancer

ZIIHERA® zanidatamab

Ongoing launch in 2L BTC

1L BTC **confirmatory trial ongoing**

Granted **conditional marketing** authorization by EC in 2L BTC for monotherapy treatment

~12,000
BTC cases annually[1] in U.S., Europe[2] and Japan

Gastroesophageal Adenocarcinoma

Granted Breakthrough Therapy designation for patients with 1L HER2+ GEA

Potential **approval and commercial launch** on or before PDUFA date

Potential to become the **new standard of care** for patients with **1L HER2+ GEA regardless of PD-L1 status**[3]

Opportunity to **explore potential in neoadjuvant** populations[3]

~63,000
GEA cases annually[1] in U.S., Europe[2] and Japan

Breast Cancer

Expanded opportunity across lines of therapy[3]:
- Post T-DXd (Ph 3 EmpowHER-BC-303 trial)
- Early BC (Ph 2 EmpowHER-BC-208 trial)
- Novel combinations (collaborations with novel TKIs from Boeringher Ingelheim and Iambic)

Potential for **novel chemo-free regimen** for **HER2+/HR+** patients[3]

Ongoing collaborations in early breast cancer:
- I-SPY2 Trial[4]
- MD Anderson collaboration

~150,000
BC cases annually[5] in U.S., Europe[2] and Japan

Other HER2-Expressing Cancers

Broad potential beyond BTC, GEA and BC in multiple HER2-expressing indications **based on compelling clinical activity from early trials**[6]:
- Colorectal
- NSCLC
- Ovarian
- Endometrial
- Pancreatic
- Bladder
- Salivary Gland
- Ampullary
- Other HER2-expressing solid tumors

Ongoing Phase 2 DiscovHER-Pan-206
- Zanidatamab monotherapy in previously-treated patients with no available treatment options

Broad Potential
Beyond BTC, GEA, and BC

[1]Incidence sources: Kantar reports, ToGA surveillance report; SEER, cancer.gov; ClearView Analysis; GLOBOCAN, Data on file; [2]Major markets, U.K, France, Germany, Spain, Italy; [3]Pending regulatory approvals; [4]NCT01042379, in collaboration with QuantumLeap Healthcare Collaborative; [5]Incidence source estimates derived from multiple sources: Decision Resources Group, Kantar Health, Jazz Market Research, data on file; [6]Funda Meric-Bernstam et al, Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study, The Lancet Oncology, Volume 23, Issue 12, 2022, Pages 1558-1570, ISSN 1470-2045, https://doi.org/10.1016/S1470-2045(22)00621-0.

Modeyso: Strong Initial Uptake and Early Launch Success

MODEYSO™ (dordaviprone) capsules 125 mg

1 Disease State Awareness & Education

CNS WHO Grade 4 glioma[1]
The most aggressive form of glioma

Invariably lethal with **rapid mortality**
Median OS: ~1 yr from diagnosis[2-5] and <6 months after recurrence[6]

Limited surgical options and **no approved therapies** for H3 K27M-mutant diffuse midline glioma[7,8]

2 Branded Campaign Launch



First and **only** FDA-approved treatment for recurrent H3 K27M-mutant diffused midline glioma

3 Launch Exceeding Expectations

Strong HCP engagement
Driving comprehensive launch plan

Digital and NPP tactics amplified; ~500 patients have received Modeyso[9]

$41M in 1Q26 net product sales;
$500M+ in U.S. peak sales potential

[1]Louis DN et al. Neuro Oncol. 2021;23(8):1231–1251; [2]Zheng L et al. Am J Surg Pathol. 2022;26:863-871; [3]Vuong et al, Frontiers in Oncology March 2022; [4]Mackay A et al. Cancer Cell. 2017;32(4):520-537; [5]Ostrom QT et al. Neuro Oncol. 2023;25:799-807; [6]Bagley et al Cancers 2025, 17(13), 2107; [7]Nabors B et al. Neuro Oncol 25(12), 2114–2116, 2023; [8]Gajjar A et al. J Natl Compr Canc Netw 2025;23(3):113–130; [9]As of March 31, 2026.

Pipeline

Focused Investments in Promising R&D Portfolio

Jazz Pharmaceuticals

Key Pipeline Programs



[1]IMforte study done in collaboration with F. Hoffmann-La Roche Ltd; [2]Lagoon study operated by partner PharmaMar.

Zanidatamab

Jazz Pharmaceuticals

Zanidatamab: Unique MOA Drives Compelling Clinical Profile and Patient Outcomes



Unique dual-targeting HER2 bispecific antibody provides differentiated treatment

Compelling and durable responses help drive **improved patient outcomes** in HER2+ patients

Favorable tolerability with manageable AE profile

Combination data supports **ability to combine with other agents** in multiple HER2+ indications

Progress Towards Realizing Full Potential of Zanidatamab





Data Support Zanidatamab as the HER2-targeted Agent of Choice in 1L HER2+ GEA

- Zanidatamab + tislelizumab provide **benefit regardless of PD-L1 status**; **2+ year mOS** for both experimental arms
- **FDA granted Priority Review under RTOR; PDUFA date of August 25, 2026**
- Submitted data for potential **NCCN Guideline** inclusion
- Data **accepted for publication** in top-tier medical journal
- Potential **approval and launch** in 1L GEA on or before PDUFA date

Focused on maximizing value of zanidatamab:

- GEA data **de-risks opportunities** across HER2+ indications, including ongoing Ph3 trial in metastatic breast cancer
- Goal to become the **HER2-targeted therapy of choice** and **cornerstone of future growth** for Jazz

Note: Data as presented by Elimova et.al ASCO GI 2026.

EmpowHER-303 Trial of Zanidatamab + Chemotherapy in Post T-DXd Patients with HER2+ Advanced BC

- Phase 3 randomized trial of patients with unresectable or metastatic HER2-positive[1] BC who have progressed on, or are intolerant to, previous T-DXd treatment
- Primary Endpoints: Progression-free survival (PFS)
  - PFS as assessed by BICR as per RECISTv1.1
- Secondary Endpoints: OS, ORR, Safety
- **Anticipate top-line data in late 2027 or early 2028**



[1]Histologically confirmed HER2-positive breast cancer according to ASCO-CAP Guidelines as evaluated by a central laboratory.

EmpowHER-208 Neoadjuvant and Adjuvant Trial of Zanidatamab + Chemotherapy in Participants with HER2+ BC

- Randomized, multicenter, open-label trial
- Eligible patients must have a tumor ≥2 cm and no clinical or radiographic evidence of distant metastasis
- Primary endpoints: Pathologic Complete Response (pCR)
- Secondary endpoints: RCB at time of surgery, EFS, PROs, safety
  - Exploratory identification of biomarkers in tumor and blood
- Initiated the Phase 2 trial in 3Q25



DiscovHER-PAN-206 Trial of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors

- Multicenter, open-label trial
- HER2 overexpression (IHC 3+) locally advanced, unresectable or metastatic disease must be determined by a sponsor designated central laboratory
- Primary endpoints: Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR
- Secondary endpoints: DOR, PFS, OS, DCR, TTR, safety
- Initiated the Phase 2 trial in 1Q25



Dordaviprone

Jazz Pharmaceuticals

Confirmatory Phase 3 ACTION Study Design

- A randomized, double-blind, placebo-controlled, multicenter international study in 510 newly diagnosed diffuse glioma patients whose tumor harbors an H3 K27M-mutation
- **Estimate an interim analysis of OS could occur in late 2026 or early 2027**

Key Eligibility Criteria

- H3 K27M-mutant diffuse glioma[1]
- Radiation therapy recently completed
- KPS ≥70 at time of randomization
- Stable steroid dose
- No prior bevacizumab
- No temozolomide within three weeks

Treatment

dordaviprone twice weekly
(625 mg dordaviprone day 1 + day 2)

dordaviprone weekly
(625 mg dordaviprone day 1 + placebo day 2)

placebo
(placebo day 1 + placebo day 2)

Endpoints

- Primary: Overall Survival
- PFS (alpha-allocated)
- Secondary: steroid response, performance status, QoL, neurologic function

ClinicalTrials.gov identifier: NCT05580562
EUCT number: 2022-502051-56-00
[1]Excludes diffuse intrinsic pontine glioma (DIPG), spinal tumors, and evidence of leptomeningeal spread of disease or cerebrospinal fluid dissemination.

JZP815

Jazz Pharmaceuticals

JZP815: Next-Generation, Pan-RAF Kinase Inhibitor

- JZP815 is a **highly selective** and **potent inhibitor** of activity against **all RAF protomers**
  - Sub-nanomolar activity against ARAF, BRAF and CRAF
- **Inhibits full spectrum** of RAF mutations and specific KRAS and NRAS driver mutations



Crystal structure of BRAF with ligand and JZP815





JZP815: Phase 1 First-in-Human Trial

- Open-label, non-randomized, multicenter trial in patients with advanced or metastatic solid tumors harboring alterations in the MAPK pathway
- **Completed: Part A:** Dose exploration phase: Determine safety, MTD and/or RP2D and PK profile
- **Progressed to expansion cohorts: Part B:** NRAS Q61 mutated solid tumors (including melanoma) and BRAF Class 2/3 mutated solid tumors
- **Primary endpoints:** Dose-limiting toxicities, objective response rate per RECIST 1.1, duration of response and AEs



JZP898

Jazz Pharmaceuticals

JZP898: Conditionally-Activated IFNα Therapy

Interferon Alpha (IFNα) Therapy

- High-dose **IFNα therapy approved for melanoma, lymphoma and leukemia**, but use **limited by systemic toxicity, modest efficacy**
- IFNα activates immune responses by engaging IFNα receptors (IFNARs) ubiquitously expressed on immune cells, or by inducing chemokines that attract myeloid and lymphoid cells to tumor site

JZP898[1] Differentiation

- Designed to be **first in-class, systemically delivered, conditionally activated IFNα molecule** for treatment of a wide variety of solid tumors
- Potential to **improve therapeutic index** of IFNα therapy by **minimizing severe toxicities associated with IFNα therapy** and **maximizing clinical benefit** when administered as monotherapy or in combination with immune checkpoint inhibitors
- Designed to systemically deliver a conditionally-activated IFNα therapy with **both IFNAR blockade** and potential for **full IFNα potency and function**



[1]WTX613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models, E Tyagi et al, poster presented at SITC Annual Meeting, Nov. 10–14, 2021; Washington, D.C.

JZP898: Phase 1 First-in-Human Trial

- Open-label, non-randomized, multicenter trial in patients with advanced or metastatic solid tumors
- Part A1: Monotherapy dose exploration phase: Determine safety and MTD
- Part A2: Progressed to cohorts in combination with pembrolizumab in renal-cell carcinoma, urothelial carcinoma, and melanoma; Determine RP2D
- Part B: Includes combination expansion using a basket design to evaluate clinical antitumor activity and safety of RP2D combination
- Primary endpoints: Dose-limiting toxicities, objective response rate and AEs



Financial Performance

Financial Strength and Discipline Enables Future Growth

Jazz Pharmaceuticals

Continued Commercial Execution + Financial Discipline

	1Q26	1Q25	Key Commentary
Total Revenues	$1,068.9M	$897.8M	• Increase primarily driven by higher Xywav, Modeyso, Zepzelca, and Epidiolex revenues
Non-GAAP Gross Margin[1]	91.6%	92.2%	• Decrease primarily due to higher royalty expenses and increased inventory provisions
Non-GAAP SG&A[1]	$308.5M	$472.3M	• Decrease primarily due to 1Q25 litigation settlement expenses of $172.0M, partially offset by inclusion of Modeyso expenses
Non-GAAP R&D[1]	$172.3M	$159.7M	• Increase primarily due to inclusion of Modeyso expenses and higher compensation-related expenses
Non-GAAP Effective Tax Rate[1]	8.9%	25.7%	• 1Q26 reflects excess tax benefits from share-based compensation; 1Q25 high due to negligible GAAP income
Weighted-Average Diluted Shares[1]	66.1M	62.6M	• Increase includes accounting effect of higher share price on convertible notes and employee stock plans
Non-GAAP EPS[1]	$6.34	$1.68	• See points cited above

[1]Non-GAAP Adjusted Gross margin, SG&A expenses, R&D expenses, ETR, and EPS are non-GAAP financial measures; for further information see "Non-GAAP Financial Measures" and reconciliation table in the Appendix.

Reaffirming Revenue and Expense Guidance[1]

	2026 Guidance (as of May 5, 2026)	Key assumptions:
Total Revenues	$4.25 - $4.50B	• Expect double-digit growth for combined rare oncology + epilepsy franchises • Expect $1.8 - $1.9B in rare sleep revenue[2] • Xywav sales expected to show flat to mid-single digit growth
Non-GAAP Gross Margin[3]	90 - 91%	• Higher sales of Modeyso and Ziihera driving higher royalties
Non-GAAP SG&A[3]	$1.26 - $1.32B	• Reduction from prior year due to 2025 legal settlements • Includes Ziihera and Modeyso launch investments
Non-GAAP R&D[3]	$725 - $775M	• Increased zanidatamab clinical trial costs • Full-year of dordaviprone related costs • Higher spend on preclinical and early clinical programs
Non-GAAP Effective Tax Rate[3]	11.5 - 13.5%	
Weighted-Average Diluted Shares[4]	66 - 67M	• Increase primarily driven by in-the-money convertible 2026 and 2030 Notes

[1]Guidance provided by Jazz Pharmaceuticals as of May 5, 2026; [2]Rare sleep includes Xywav, Xyrem and high-sodium AG royalty revenues; [3]Non-GAAP Adjusted Gross margin, SG&A expenses, R&D expenses, and ETR are non-GAAP financial measures; for further information see "Non-GAAP Financial Measures" and reconciliation table in the Appendix; [4]Prior guidance as of February 24, 2026 was 65-66M weighted-average ordinary shares outstanding. Guidance assumes inclusion of shares outstanding in relation to the Exchangeable Senior Notes, given the company's share price exceeds the conversion prices of the Exchangeable Senior Notes.

Well Positioned to Succeed in Rare Disease

Research and Development

Commercial

Corporate Development

Strong Financial Position

~$1.1B
Total revenues[1]

~$408M
Cash from operations[1]

~$2.9B
Cash, cash equivalents, and investments[2]

[1]For the quarter ended March 31, 2026; [2]As of March 31, 2026.

Appendix

Glossary

Acronym	Definition
1L	First-line
1LM	First-line maintenance
2L	Second-line
AE	Adverse event
AG	Authorized generic
ALL / LBL	Acute lymphoblastic leukaemia / lymphoblastic lymphoma
ANI	Adjusted net income
ASCO	American Society of Clinical Oncology
ASCO GI	American Society of Clinical Oncology Gastrointestinal Cancers Symposium
B	Billions
BC	Breast cancer
BICR	Blinded independent central review
BID	Twice daily dosing
BTC	Biliary tract cancer
Chimerix Acquisition	Our acquisition of Chimerix on April 21, 2025
CNS	Central Nervous System
DCR	Disease control rate
DOR	Duration of response
EC	European Commission
ECOG PS	Eastern Cooperative Oncology Group Performance Status
EFS	Event-free survival
EPS	Earnings per share
ES	Extensive-stage
ETR	Effective tax rate
Exchangeable senior notes	2026 Notes and 2030 Notes
FDA	U.S. Food and Drug Administration
GAAP	Generally accepted accounting principles

Acronym	Definition
GEA	Gastroesophageal adenocarcinoma
HCP	Healthcare provider
HER2	Human epidermal growth factor receptor 2
HR+	Hormone receptor-positive
IH	Idiopathic hypersomnia
IHC	Immunohistochemistry
KPS	Karnofsky Performance Scale
KRAS	Kirsten Rat Sarcoma viral oncogene homolog
LGS	Lennox-gastaut syndrome
LPS	Loss per share
M	Millions
MAPK	Mitogen-activated protein kinases
MOA	Mechanism of action
MTD	Maximum tolerated dose
NCCN	National Comprehensive Cancer Network
NPP	Non-personal promotion
NRAS	Neuroblastoma ras viral oncogene homolog
NSCLC	Non-small cell lung cancer
ORR	Overall response rate
OS	Overall survival
pCR	Pathological complete response
PD-L1	Programmed Death-Ligand 1
PK	Pharmacokinetics
PFS	Progression-free survival
PRO	Patient-reported outcome
PRV	Priority Review Voucher
QoL	Quality of Life
R&D	Research and development

Acronym	Definition
RD	Residual disease
RAF	Rapidly accelerated fibrosarcoma
RAS	Rat Sarcoma Virus
RCB	Residual cancer burden
RECISTv1.1	Response Evaluation Criteria in Solid Tumors, version 1.1
RP2D	Recommended phase 2 dose
RTOR	Real-time oncology review
sBLA	Supplemental biologics license application
SCLC	Small-cell lung cancer
SG&A	Selling, general and administrative
T-DM1	Ado-trastuzumab emtansine
T-DXd	Trastuzumab deruxtecan
TKI	Tyrosine kinase inhibitors
TME	Tumor microenvironment
TSC	Tuberous sclerosis complex
TTR	Time to response
WHO	World Health Organization
YoY	Year-over-year, 1Q26 vs. 1Q25

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information[1]

(In millions, except percentages)	Three Months Ended March 31, 2026	2025
GAAP gross margin on total revenues	**87.5 %**	**88.3 %**
Acquisition accounting inventory fair value step-up	3.5 %	3.3 %
Share-based compensation expense	0.6 %	0.6 %
Non-GAAP gross margin on total revenues[1]	91.6 %	92.2 %
GAAP SG&A expenses	**$352.7**	**$514.0**
Share-based compensation expense	(44.2)	(41.7)
Non-GAAP SG&A expenses[1]	308.5	472.3
GAAP R&D expenses	**$196.0**	**$180.7**
Share-based compensation expense	(23.7)	(21.0)
Non-GAAP R&D expenses[1]	172.3	159.7
GAAP ETR	**2.0 %**	**16.2 %**
Income tax effect of GAAP to non-GAAP reconciling items	6.9 %	9.5 %
Non-GAAP ETR[1]	8.9 %	25.7 %

[1]Non-GAAP Gross Margin, SG&A expenses, R&D expenses and ETR are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures".

Reconciliation of GAAP to Non-GAAP Adjusted[1] 2026 Guidance

(In millions, except percentages)	Projected Range	
	Low	High
GAAP gross margin on total revenues	**89 %**	**90 %**
Acquisition accounting inventory fair value step-up	1 %	1 %
Non-GAAP gross margin on total revenues[1]	90 %	91 %
GAAP SG&A expenses	**$1,424**	**$1,497**
Share-based compensation expense	(164)	(177)
Non-GAAP SG&A expenses[1]	1,260	1,320
GAAP R&D expenses	**$811**	**$867**
Share-based compensation expense	(86)	(92)
Non-GAAP R&D expenses[1]	725	775
GAAP ETR	**0 %**	**10 %**
Income tax effect of GAAP to non-GAAP reconciling items	11.5 %	3.5 %
Non-GAAP ETR[1]	11.5 %	13.5 %

[1]Non-GAAP Gross Margin, SG&A expenses, R&D expenses and ETR are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures".

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information[1]

In millions, except per share amounts (unaudited)	Three Months Ended March 31, 2026		2025	
	Net Income	Diluted EPS	Net Income (Loss)	Diluted EPS/(LPS)
GAAP reported	**$293.1**	**$4.43**	**$(92.5)**	**$(1.52)**
Intangible asset amortization	172.3	2.61	154.4	2.47
Share-based compensation expense	74.5	1.13	67.7	1.08
Acquisition accounting inventory fair value step-up	37.5	0.57	29.9	0.48
Gain on sale of PRV	(122.8)	(1.86)	—	—
Income tax effect of above adjustments	(35.1)	(0.54)	(54.3)	(0.87)
Effect of potentially dilutive ordinary shares on non-GAAP adjusted EPS	—	—	—	0.04
Non-GAAP adjusted[1]	$419.5	$6.34	$105.2	$1.68
Weighted-average ordinary shares used in diluted per share calculations – GAAP	**66.1**		**61.0**	
Dilutive effect of employee equity incentive and purchase plans	—		1.6	
Weighted-average ordinary shares used in diluted per share calculations – non-GAAP[1]	66.1		62.6	

[1]Non-GAAP adjusted net income (and the related per share measure) are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures”.